New hope for pancreatic cancer patients: experimental immunotherapy offered outside clinical trial

This program provides access to an experimental immunotherapy called ELI-002 7P for patients with a specific type of pancreatic cancer (with KRAS or NRAS mutations) who are at high risk of the cancer coming back after surgery. It is for patients who have no other good treatment options and cannot join a standard clinical trial. The treatment aims to train the patient's immune system to recognize and attack cancer cells to prevent or delay the cancer's return.